Abstract
To assess the effects of alpha-tocopherol and ascorbic acid on skin thickening and lung function in patients with early diffuse systemic sclerosis (SSc), thirteen patients with early diffuse SSc, with positive anti-topoisomerase-I antibody, high skin thickening progression rate (STPR ≥ 12/year) and decreased lung diffusing capacity (DLCO ≤ 75%) were included in this study. Patients were randomized into two subgroups: Subgroup A—six patients, treated with intravenous cyclophosphamide (CyP) (500 mg/m2 of body surface monthly) and antioxidants (alpha-tocopherol 400 IU/day and ascorbic acid 1,000 mg/day), and Subgroup B—seven patients, who received CyP without antioxidants. In both subgroups, effects of treatment on skin thickening and lung function were evaluated by comparison of the modified Rodnan skin score (MRSS), STPR, forced vital capacity (FVC), transfer-factor (DLCO) and diffusing coefficient for carbon monoxide (DLCO/VA) at baseline and 1 month after the sixth pulse of CyP. The mean MRSS did not change from baseline to the end of the follow-up in subgroup A (15.7 vs. 16.4, P = 0.50), but it increased significantly in subgroup B (17.9 vs. 23.6, P = 0.03). Although the mean STPR decreased notably in both subgroups of patients (in subgroup A–from 18.9/year to 2.2/year, P = 0.03, and in subgroup B–from 17.5/year to 8.6/year, P = 0.03), the mean STPR at the end of the treatment period was significantly lower in subgroup A (2.2/year vs. 8.6/year, P = 0.04). The mean value of FVC did not change either in subgroup A (91.0–87%, P = 0.2) or in subgroup B (from 101.2 to 99.7%, P = 0.7). Parameters of lung diffusing capacity improved somewhat in subgroup A (DLCO from 55.7 to 62.0% and DLCO/VA from 68.7 to 74.2%) and decreased in subgroup B (DLCO from 66.2 to 60.6% and DLCO/VA from 76.9 to 71.6%), but differences were not statistically significant. After 6 months of therapy, patients treated with CyP and antioxidants had a significantly lower STPR, compared to patients treated with CyP only. Lung function parameters remained stable in both subgroups. However, lung diffusing capacity improved slightly, without statistical significance, in patients treated with CyP and antioxidants, and it deteriorated in patients without antioxidants.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Herrick AL, Matucci M (2001) The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 19:4–8
Blake DR, Winyard P, Scott DGI et al (1985) Endothelial cytotoxicity in inflammatory vascular diseases–the possible role of oxidized lipoproteins. Ann Rheum Dis 44:176–182
Bruckdorfer KR, Hillary JB, Bunce T et al (1994) Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 38:1060–1067
Yamamoto T, Katayama I, Nichioka K (1998) Nitric oxide production and inducible nitric oxide synthetase expression in systemic sclerosis. J Rheumatol 25:314–317
Cotton SA, Herrick AL, Joyson MIV et al (1999) Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 189:273–278
Yamamoto T, Eawada Y, Katayama I et al (1998) Increased production of nitric oxide stimulated by interleukin-1b in peripheral blood mononuclear cells in patients with systemic sclerosis. Br J Rheumatol 37:1123–1125
Cavallo G, Sabadini L, Rollo L et al (1999) Nitric oxide synthesis in peripheral blood mononuclear and polymorphonuclear cells from patients with systemic sclerosis. Rheumatology 38:1301–1304
Lundberg AC et al (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51(10):1143–1148
Herrick AL, Worthington H, Rieley F et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653
Teh LS, Johns CW, Shaffer JL et al (1997) Ascorbic acid and absorption in patients with systemic sclerosis. J Rheumatol 24:2353–2357
Steen V, Medsger T (2000) Severe organ involvement in patients with diffuse scleroderma. Arthritis Rheum 43:2437–2444
Denton CP, Bunce TD, Dorado MB et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology 38:309–315
Herrick AL, Hollis S, Schofield D et al (2000) A double-blind, placebo controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356
Herrera E, Barbas C (2001) Vitamin E: action, metabolism and perspectives. J Physiol Biochem 57(2):43–56
Packer L, Weber SU, Rimbach G (2001) Molecular aspects of alpha-tocotrienol antioxidant action and cell signaling. J Nutr 131(2):369–373
Cominacini L, Garbin U, Pasini AF et al (1997) Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. Free Radic Biol Med 22(1–2):117–127
Chan AC, Wagner M, Kennedy C et al (1998) Vitamin E upregulates arachidonic acid release and phospholipase A2 in megakaryocytes. Mol Cell Biochem 189(1–2):153–159
Acknowledgments
This study had local ethics committee approval.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ostojic, P., Damjanov, N. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis. Rheumatol Int 31, 1051–1054 (2011). https://doi.org/10.1007/s00296-010-1398-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1398-1